Epinephrine

證據等級: L5

預測適應症: 10 個

Epinephrine: From Anaphylaxis & Bronchospasm to Obstructive Lung Disease

One-Sentence Summary

Epinephrine (adrenaline) is a naturally occurring catecholamine and cornerstone emergency medication, classically used for anaphylaxis, cardiac arrest, and acute severe bronchospasm; it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Obstructive Lung Disease (particularly acute bronchiolitis in infants), with 2 Cochrane systematic reviews, 1 pivotal Phase 3 RCT (n=864), and multiple completed RCTs currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Anaphylaxis; acute severe bronchospasm (no Singapore registration on record)
Predicted New Indication	Obstructive Lung Disease (Bronchiolitis)
TxGNN Prediction Score	99.71%
Evidence Level	L1
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Epinephrine acts simultaneously on two classes of adrenergic receptors, giving it a dual advantage in managing acute airway obstruction. Stimulation of β2-adrenergic receptors on bronchial smooth muscle causes rapid bronchodilation, while activation of α1-adrenergic receptors on mucosal blood vessels induces vasoconstriction, reducing submucosal edema and secretion. This combined mechanism directly addresses the two dominant pathophysiological processes — bronchospasm and mucosal swelling — that underlie obstructive lung disease.

In infant bronchiolitis, the most clinically studied obstructive lung disease subtype in this context, the airway is compromised by viral-induced inflammation (typically RSV or parainfluenza), mucus plugging, and mucosal congestion. Unlike selective β2-agonists such as salbutamol, nebulized epinephrine's additional α1 activity targets mucosal congestion specifically, explaining its superior short-term efficacy observed in multiple head-to-head trials. The drug has been used in this setting for several decades, and its therapeutic role is reflected in emergency paediatric protocols internationally.

The TxGNN prediction score of 99.71% is therefore mechanistically well-grounded. Two Cochrane systematic reviews confirm consistent short-term clinical benefit, and a recently completed large Phase 3 RCT (n=864) further validates the therapeutic direction. While epinephrine's effect in bronchiolitis is symptom-directed rather than disease-modifying, its role as an acute first-line intervention is well established and the mechanistic rationale for the TxGNN prediction is clear.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03567473	Phase 3	Completed	864	Multicentre Phase 3 RCT: inhaled epinephrine + oral dexamethasone vs. double placebo in infants with bronchiolitis presenting to ED; primary endpoint was hospitalization rate at 7 days — highest-quality pivotal trial for this indication
NCT03614273	N/A	Completed	60	RCT directly comparing nebulized 3% hypertonic saline vs. nebulized adrenaline in bronchiolitis; also assessed non-responders to initial therapy to guide stepwise management
NCT01834820	Phase 4	Completed	120	Pilot RCT of triple therapy (epinephrine + dexamethasone + hypertonic saline) in infant bronchiolitis; measured impact on hospital admission rate
NCT02586961	Phase 2/3	Terminated	195	Multicentre RCT: nebulized adrenaline + high-dose oral betamethasone in bronchiolitis at paediatric ED; designed to confirm reduction in hospitalization rate
NCT00622817	N/A	Completed	65	Double-blind RCT: adrenaline inhalation vs. xylometazoline HCl nasal drops for bronchiolitis; tested hypothesis of equivalent efficacy
NCT01705964	Phase 4	Completed	49	RCT: intramuscular epinephrine 1:1000 as adjunct to inhaled β2-agonists in children with severe acute asthma exacerbation in ED
NCT00114478	N/A	Unknown	600	Head-to-head comparison of epinephrine vs. albuterol for bronchiolitis; one of the largest enrolment trials for this question
NCT01255709	Phase 2	Completed	24	Pharmacokinetic crossover study of epinephrine HFA-MDI inhaler (E004) using deuterium-labelled tracer to distinguish exogenous from endogenous epinephrine
NCT01143051	Phase 1/2	Completed	24	PK and safety evaluation of inhaled epinephrine HFA aerosol (E004) under augmented dosing in healthy volunteers; supports inhaled route characterisation
NCT01216553	Phase 4	Unknown	135	Matched case-control study of home oxygen therapy with nebulized epinephrine (0.1% in bromhexine) or hypertonic saline for outpatient bronchiolitis management

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21678340	2011	Cochrane SR / Meta-analysis	Cochrane Database Syst Rev	Comprehensive systematic review and meta-analysis of epinephrine for acute bronchiolitis; demonstrated short-term improvement in clinical severity scores vs. placebo
14974006	2004	Cochrane SR	Cochrane Database Syst Rev	Earlier Cochrane review confirming modest short-term clinical benefit of epinephrine as bronchodilator in mild-to-moderate bronchiolitis
21486501	2011	Clinical Review	BMJ Clinical Evidence	Evidence-based management overview of bronchiolitis in infants; epinephrine assessed among bronchodilators for hospital and outpatient settings
30488718	2019	Review	Expert Rev Respir Med	Decade-long review of therapeutic strategies for paediatric bronchiolitis; racemic epinephrine, systemic corticosteroids, hypertonic saline, and high-flow oxygen compared
19444115	2009	Review	Curr Opin Pediatrics	Updated review of all epinephrine applications in paediatric emergencies, including bronchiolitis, croup, and anaphylaxis; highlights dosing and route considerations
19135584	2009	Review	Pediatr Clin North Am	Mechanistic and clinical evidence for nebulized adrenaline in acute bronchiolitis and croup; discusses symptom-relief role vs. disease modification
4606289	1974	Clinical Study	Clin Pharmacol Ther	Comparative study of bronchodilator effects of terbutaline vs. epinephrine in patients with obstructive lung disease; early mechanistic evidence
19450362	2007	Clinical Review	BMJ Clinical Evidence	Bronchiolitis evidence review; evaluates epinephrine alongside supportive therapies; discusses limitations of bronchodilator use in outpatient setting
6777857	1980	Cohort Study	Scand J Clin Lab Invest	Elevated plasma noradrenaline in chronic obstructive lung disease patients; inverse correlation with arterial oxygen saturation, supporting catecholamine involvement in disease physiology
30856157	2019	Drug Review	Med Letter Drugs Ther	OTC re-approval of Primatene Mist (epinephrine HFA inhaler) by FDA for mild intermittent asthma bronchospasm; regulatory milestone for inhaled epinephrine formulations

Singapore Market Information

Epinephrine currently has no registered products in Singapore (HSA). There are no licence entries to display. This represents a critical regulatory gap that must be addressed before any structured repurposing programme can proceed.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two Cochrane systematic reviews and a completed Phase 3 multicentre RCT (n=864) together establish L1-level evidence that inhaled/nebulized epinephrine provides meaningful short-term clinical benefit in obstructive lung disease (particularly infant bronchiolitis), with a clear and well-characterized adrenergic mechanism of action. The TxGNN prediction is strongly supported by clinical and mechanistic evidence. However, epinephrine carries no Singapore registration, and complete safety, contraindication, and drug interaction data for the local regulatory context has not been assembled.

To proceed, the following is needed:

HSA registration pathway assessment for epinephrine nebulizer solution and/or HFA-MDI inhaler formulations
Full safety profile documentation: retrieve TFDA, EMA, and FDA-approved package inserts to extract warnings, contraindications, and monitoring requirements
Drug-drug interaction data (DrugBank API query; particular attention to MAO inhibitors, β-blockers, tricyclic antidepressants, and halogenated anaesthetics)
Formal target population definition: acute infant bronchiolitis vs. broader obstructive lung disease spectrum
Safety monitoring plan for high-risk subgroups (premature neonates, infants with congenital heart disease, patients with arrhythmia risk)
Formulation strategy: determine whether existing international nebulizer solutions or the newly re-approved HFA-MDI (Primatene Mist) format is appropriate for the Singapore context
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.